Application Deadline
August 31, 2019

Senior Molecular Biologist / Next-Generation Sequencing

Today, there is a need for more accurate and personalized RNA-based cancer diagnostics. RNA visualization and sequencing are an integrated part of R&D programs in the pharmaceutical industry, and are increasingly used at cancer centers, institutes and hospitals to provide more accurate diagnosis and subsequent personalized treatment regimens for patients.

Our biotech company, MultiplexDX, aims to drastically increase the number of cancer survivors through personalized diagnostics that lead to tailored, effective, and life-saving treatment. We want to bring to market a reliable, accurate, quantitate, cost-effective, and multiplexed diagnostic test for cancer, which can accurately identify and quantify cancer biomarkers in human tissues.

The position

We are looking for an experienced Senior Molecular Biologist Next-Generation Sequencing to take the lead in planning, conducting, and optimizing RNA-based next-generation sequencing experiments.

In this multifaceted role, you will help advance our next pipeline of designed diagnostic products, solve technical obstacles, test different concepts in the laboratory, read scientific papers, track R&D costs, study patents, and generate new ideas in collaboration with our team of innovative Molecular Biologists.

You will report to the Director of Research & Development and Chief Operating Officer and be based at the headquarters in Bratislava, Slovakia.


  • Plan, conduct, and optimize RNA-based next-generation sequencing experiments;
  • Experience with molecular biology techniques, including RNA extraction/purification, PCR, qPCR, RNA/small RNA NGS library preparation, RNA quality control (NanoDrop™, Qubit™, Bioanalyzer/Tapestation), gel electrophoresis, etc.;
  • Operation and maintenance of laboratory & analytical equipment;
  • Generate new concepts and ideas in collaboration with the team;
  • Test concepts in the laboratory;
  • Documentation of experimental work, analysis of data, documenting and presenting results;
  • Preparation of written methods and SOPs;
  • Evaluate and document the new product or method;
  • Presentation of research findings manuscripts, conferences, and to potential partners;
  • Map, document, and navigate through IPR;
  • Report on freedom to operate, technical risks, strengths, and cost estimations;
  • Communicate with partners and customers to use feedback in development;
  • Management and mentoring of research associates;
  • Help to set the company’s strategic direction in terms of cancer diagnostics area of interest.


  • PhD in Molecular Biology (or related field) with extensive training and practical laboratory experience in next-generation sequencing;
  • MSc degree holders will be considered if they can demonstrate significant experience;
  • 2 years hands-on laboratory experience with RNA (in particular small RNA) library preparation for next-generation sequencing and other molecular biology techniques (PCR, qPCR, gel electrophoresis) from biotech or similar industry is preferred;
  • Experience in bioinformatics or knowledge of NGS bioinformatic workflows is an advantage;
  • Ability to work independently as well as part of a multidisciplinary team is essential;
  • Excellent analytical and systematic troubleshooting skills;
  • Strong creative skills and out-of-the-box thinking;
  • Demonstration of goal-oriented, hands-on, and innovative approach to problem solving;
  • Excellent written and oral communication skills (English is our working language);
  • Excellent organizational and reasoning skills are a must;
  • Experience reading and writing patent applications is preferred.

We offer

We offer a great job with development opportunities in a highly motivating and professional environment. You may be looking for a new career path or you may simply be looking to contribute to a small, hard-working organization with the ambition to make a difference.

You will be offered the opportunity to spearhead the next ground-breaking diagnostic technologies involving RNA-based next-generation sequencing.

The job will be challenging and rewarding at the same time. You will have world class colleagues, flexible working hours, 5 weeks of paid holiday, and a negotiable salary commensurate to your qualifications (starting from €2000/month).

Application deadline

Application deadline is August 31st, 2019. Please send the application including your CV or resume with the names of 3 references and a cover letter to

Your application will be treated in accordance with our policies for processing of personal data and the General Data Protection Regulation of the EU.


MultiplexDX’s diagnostic products combine specific, precise, automated, high-throughput, multiplexed and quantitative RNA visualization and sequencing to come up with a specific“barcode” for each cancer, which suggests a specific, personalized treatment strategy. In MultiplexDX’s diagnostic tests, multiplexing stands for cross-validating test results by using two independent perspectives, visualization and sequencing. This multiplexed platform provides the most accurate clinical parameters of a patient’s cancer profile, which enables an oncologist to make an evidence-based decision and target treatment quickly, directly, and more accurately.

For additional information, please contact

Peter Kilian
Ilkovičova 8
84104 Bratislava, Slovakia

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter